John EadePresident & Director of Portfolio Strategies
John is chairman and CEO of Argus Research Group and president of Argus Research Company. Over the years, his responsibilities at Argus have included chairing the Investment Policy Committee as then director of research; helping form the firm s overall investment strategy; writing a weekly investment column; and authoring the flagship Portfolio Selector report. He has also provided coverage of the Healthcare, Financial and Consumer sectors. John has been with Argus since 1989. He has an MBA in Finance from New York University s Stern School of Business and a Bachelor s degree in Journalism from Northwestern University s Medill School of Journalism. He has been interviewed and quoted extensively in The New York Times, Forbes, Time, Fortune and Money magazines, and has been a frequent guest on CNBC, CNN, CBS News, ABC News and the Bloomberg Radio and Television networks. John is a founder and board member of the Investorside Resear
If Robinhood got one thing spot on, it s that free sells.
Prior to setting off a stock market firestorm last week, investors in Robinhood, the Menlo Park, California-based trading platform, were only too happy to keep fueling its growth. Now they have no choice.
Robinhood faced crippling cash demands brought on by a Reddit subgroup named WallStreetBets, which was driving up the stock price of companies, including GameStop and AMC, that had been targeted by well-known short sellers. The stated goal: squeeze the shorts. The ensuing volume of orders pushed Robinhood into tricky territory with its cash position, when the clearinghouse that helps the firm process and settle trades asked the company to put up more capital to meet margin requirements. Robinhood responded by restricting trading on 13 stocks on Thursday, infuriating the WallStreetBets investors and sending prices on those stocks down.
Jericho Project Welcomes CFO and COO of charity: water Aditi Deeg to Its Board
Share Article
Aditi Deeg, Jericho Project Board Member
We are honored to have Aditi Deeg bring her extensive leadership experience to our Board. We welcome her tremendous talent in achieving financial efficiencies while motivating teams with optimism as we move forward as an organization. Jericho Project Board President Mimi Boublik NEW YORK (PRWEB) January 29, 2021 Jericho Project, a nationally-acclaimed nonprofit ending homelessness at its roots, has welcomed Aditi Deeg, Chief Financial and Operating Officer at charity: water and strategic nonprofit leader, to its Board of Directors.
Published: Jan 29, 2021
BOSTON and LONDON, Jan. 29, 2021 (GLOBE NEWSWIRE) Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the appointment of Braden Parker to the role of Chief Commercial Officer (CCO). In this capacity, Mr. Parker will oversee all aspects of commercial strategy, planning and operations for the company. Mr. Parker is a seasoned commercial leader with more than 20 years of experience in the healthcare and biotech industry, including deep rare disease and gene therapy experience. Mr. Parker’s previous positions include commercial leadership roles at Celgene, NPS Pharma (Shire) and PTC Therapeutics, where he led the company’s first U.S. product launch in Duchenne muscular dystrophy and oversaw the strategic planning for their gene therapy business. Most recently, Mr. Parker served as Orchard’s senior vice president and general manager for North America.